Respiratory infection test kit RP2.1

coronavirusSARS-COV-2influenza A

PCR and COVID-19 go hand in hand, but the latter is no longer the predominate upper respiratory tract infection (URTI) in circulation. Help differentiate respiratory diagnoses with the help of the BIOFIRE RP2.1 Panel, Respiratory Testing, Elevated The BIOFIRE RP2.1 Panel is a frontline test to help clinicians more quickly diagnose URTIs, including COVID-19, influenza, RSV, and many others. The multiplex PCR panel identifies 22 pathogen targets within a time frame that potentially facilitates better-informed diagnosis and treatment of patients. The BIOFIRE RP2.1 Panel can provide the essential combination of speed, accuracy, and comprehensiveness to enable a rapid, definitive identification of a pathogen. COMPREHENSIVE Simultaneously tests for 22 targets, including RSV, SARS-CoV-2, and influenza Answers You Need, When You Need Them Cough, fever, runny nose, fatigue. These symptoms can be assigned to any number of respiratory infections, making diagnosis a potentially dangerous guessing game. To improve patient outcomes and therapy management, your test should give you actionable answers as quickly as possible. Here’s how our multiplex molecular test addresses that challenge. Identify Pathogens More Often The BIOFIRE RP2.1 Panel has a positivity rate of 87.2% compared to 30.2% in rapid antigen tests.2 Faster Time to Results The panel’s turnaround time for influenza and non-influenza viruses, respectively, is 1.7 hours and 1.5 hours. This compares to 7.7 hours and 13.5 hours, respectively, in standard of care.3 Improve Antimicrobial Therapy The RP2.1 Panel has been shown to improve targeted broad-spectrum antimicrobial therapy